Skip to main content
Fig. 2 | Orphanet Journal of Rare Diseases

Fig. 2

From: Critical appraisal of arguments for the delayed-start design proposed as alternative to the parallel-group randomized clinical trial design in the field of rare disease

Fig. 2

Graphical display of the delayed-start design. At baseline (time 0), patients are randomly assigned to receive either placebo (delayed-start group) or the investigational treatment (early-start group) and they are followed over an extended period of time. Then, patients in the placebo group switch to the investigational treatment until the end of the trial (active treatment phase)

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172